135 related articles for article (PubMed ID: 22534770)
1. Differences in allele frequencies of autosomal dominant hypercholesterolemia SNPs in the Malaysian population.
Alex L; Chahil JK; Lye SH; Bagali P; Ler LW
J Hum Genet; 2012 Jun; 57(6):358-62. PubMed ID: 22534770
[TBL] [Abstract][Full Text] [Related]
2. Genetic polymorphisms in LDLR, APOB, PCSK9 and other lipid related genes associated with familial hypercholesterolemia in Malaysia.
Lye SH; Chahil JK; Bagali P; Alex L; Vadivelu J; Ahmad WA; Chan SP; Thong MK; Zain SM; Mohamed R
PLoS One; 2013; 8(4):e60729. PubMed ID: 23593297
[TBL] [Abstract][Full Text] [Related]
3. Genotypic and phenotypic features in homozygous familial hypercholesterolemia caused by proprotein convertase subtilisin/kexin type 9 (PCSK9) gain-of-function mutation.
Mabuchi H; Nohara A; Noguchi T; Kobayashi J; Kawashiri MA; Inoue T; Mori M; Tada H; Nakanishi C; Yagi K; Yamagishi M; Ueda K; Takegoshi T; Miyamoto S; Inazu A; Koizumi J;
Atherosclerosis; 2014 Sep; 236(1):54-61. PubMed ID: 25014035
[TBL] [Abstract][Full Text] [Related]
4. Plasma lipoprotein(a) levels in patients with homozygous autosomal dominant hypercholesterolemia.
Sjouke B; Yahya R; Tanck MWT; Defesche JC; de Graaf J; Wiegman A; Kastelein JJP; Mulder MT; Hovingh GK; Roeters van Lennep JE
J Clin Lipidol; 2017; 11(2):507-514. PubMed ID: 28502508
[TBL] [Abstract][Full Text] [Related]
5. Genetic analysis of familial hypercholesterolemia in Asian Indians: A single-center study.
Setia N; Movva S; Balakrishnan P; Biji IK; Sawhney JPS; Puri R; Arora A; Puri RD; Saxena R; Mishra S; Apte S; Kulshrestha S; Ramprasad VL; Verma IC
J Clin Lipidol; 2020; 14(1):35-45. PubMed ID: 32044282
[TBL] [Abstract][Full Text] [Related]
6. The genetic spectrum of familial hypercholesterolemia in the central south region of China.
Xiang R; Fan LL; Lin MJ; Li JJ; Shi XY; Jin JY; Liu YX; Chen YQ; Xia K; Zhao SP
Atherosclerosis; 2017 Mar; 258():84-88. PubMed ID: 28235710
[TBL] [Abstract][Full Text] [Related]
7. Molecular genetics of familial hypercholesterolemia in Israel-revisited.
Durst R; Ibe UK; Shpitzen S; Schurr D; Eliav O; Futema M; Whittall R; Szalat A; Meiner V; Knobler H; Gavish D; Henkin Y; Ellis A; Rubinstein A; Harats D; Bitzur R; Hershkovitz B; Humphries SE; Leitersdorf E
Atherosclerosis; 2017 Feb; 257():55-63. PubMed ID: 28104544
[TBL] [Abstract][Full Text] [Related]
8. Targeted Genetic Analysis in a Chinese Cohort of 208 Patients Related to Familial Hypercholesterolemia.
Wang H; Yang H; Liu Z; Cui K; Zhang Y; Zhang Y; Zhao K; Yin K; Li W; Zhou Z
J Atheroscler Thromb; 2020 Dec; 27(12):1288-1298. PubMed ID: 32759540
[TBL] [Abstract][Full Text] [Related]
9. A new PCSK9 gene promoter variant affects gene expression and causes autosomal dominant hypercholesterolemia.
Blesa S; Vernia S; Garcia-Garcia AB; Martinez-Hervas S; Ivorra C; Gonzalez-Albert V; Ascaso JF; Martín-Escudero JC; Real JT; Carmena R; Casado M; Chaves FJ
J Clin Endocrinol Metab; 2008 Sep; 93(9):3577-83. PubMed ID: 18559913
[TBL] [Abstract][Full Text] [Related]
10. Proprotein convertase subtilisin/kexin 9 V4I variant with LDLR mutations modifies the phenotype of familial hypercholesterolemia.
Ohta N; Hori M; Takahashi A; Ogura M; Makino H; Tamanaha T; Fujiyama H; Miyamoto Y; Harada-Shiba M
J Clin Lipidol; 2016; 10(3):547-555.e5. PubMed ID: 27206942
[TBL] [Abstract][Full Text] [Related]
11. Screening of common genetic variants in the APOB gene related to familial hypercholesterolemia in a Saudi population: A case-control study.
Batais MA; Almigbal TH; Shaik NA; Alharbi FK; Alharbi KK; Ali Khan I
Medicine (Baltimore); 2019 Jan; 98(4):e14247. PubMed ID: 30681615
[TBL] [Abstract][Full Text] [Related]
12. Clinical characterization and mutation spectrum of German patients with familial hypercholesterolemia.
Grenkowitz T; Kassner U; Wühle-Demuth M; Salewsky B; Rosada A; Zemojtel T; Hopfenmüller W; Isermann B; Borucki K; Heigl F; Laufs U; Wagner S; Kleber ME; Binner P; März W; Steinhagen-Thiessen E; Demuth I
Atherosclerosis; 2016 Oct; 253():88-93. PubMed ID: 27596133
[TBL] [Abstract][Full Text] [Related]
13. Global molecular analysis and APOE mutations in a cohort of autosomal dominant hypercholesterolemia patients in France.
Wintjens R; Bozon D; Belabbas K; MBou F; Girardet JP; Tounian P; Jolly M; Boccara F; Cohen A; Karsenty A; Dubern B; Carel JC; Azar-Kolakez A; Feillet F; Labarthe F; Gorsky AM; Horovitz A; Tamarindi C; Kieffer P; Lienhardt A; Lascols O; Di Filippo M; Dufernez F
J Lipid Res; 2016 Mar; 57(3):482-91. PubMed ID: 26802169
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of polygenic cause in Korean patients with familial hypercholesterolemia - A study supported by Korean Society of Lipidology and Atherosclerosis.
Kwon M; Han SM; Kim DI; Rhee MY; Lee BK; Ahn YK; Cho BR; Woo J; Hur SH; Jeong JO; Jang Y; Lee SH; Lee JH
Atherosclerosis; 2015 Sep; 242(1):8-12. PubMed ID: 26160041
[TBL] [Abstract][Full Text] [Related]
15. LDLR and ApoB are major genetic causes of autosomal dominant hypercholesterolemia in a Taiwanese population.
Yang KC; Su YN; Shew JY; Yang KY; Tseng WK; Wu CC; Lee YT
J Formos Med Assoc; 2007 Oct; 106(10):799-807. PubMed ID: 17964958
[TBL] [Abstract][Full Text] [Related]
16. Low prevalence of mutations in known loci for autosomal dominant hypercholesterolemia in a multiethnic patient cohort.
Ahmad Z; Adams-Huet B; Chen C; Garg A
Circ Cardiovasc Genet; 2012 Dec; 5(6):666-75. PubMed ID: 23064986
[TBL] [Abstract][Full Text] [Related]
17. APOE p.Leu167del mutation in familial hypercholesterolemia.
Awan Z; Choi HY; Stitziel N; Ruel I; Bamimore MA; Husa R; Gagnon MH; Wang RH; Peloso GM; Hegele RA; Seidah NG; Kathiresan S; Genest J
Atherosclerosis; 2013 Dec; 231(2):218-22. PubMed ID: 24267230
[TBL] [Abstract][Full Text] [Related]
18. Molecular spectrum of autosomal dominant hypercholesterolemia in France.
Marduel M; Carrié A; Sassolas A; Devillers M; Carreau V; Di Filippo M; Erlich D; Abifadel M; Marques-Pinheiro A; Munnich A; Junien C; ; Boileau C; Varret M; Rabès JP
Hum Mutat; 2010 Nov; 31(11):E1811-24. PubMed ID: 20809525
[TBL] [Abstract][Full Text] [Related]
19. Novel PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9) Variants in Patients With Familial Hypercholesterolemia From Cape Town.
Huijgen R; Blom DJ; Hartgers ML; Chemello K; Benito-Vicente A; Uribe KB; Behardien Z; Blackhurst DM; Brice BC; Defesche JC; de Jong AG; Jooste RJ; Solomon GAE; Wolmarans KH; Hovingh GK; Martin C; Lambert G; Marais AD
Arterioscler Thromb Vasc Biol; 2021 Feb; 41(2):934-943. PubMed ID: 33147992
[TBL] [Abstract][Full Text] [Related]
20. Effect of mutations in LDLR and PCSK9 genes on phenotypic variability in Tunisian familial hypercholesterolemia patients.
Slimani A; Jelassi A; Jguirim I; Najah M; Rebhi L; Omezzine A; Maatouk F; Hamda KB; Kacem M; Rabès JP; Abifadel M; Boileau C; Rouis M; Slimane MN; Varret M
Atherosclerosis; 2012 May; 222(1):158-66. PubMed ID: 22417841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
